NervGen Pharma Corp (NGENF)

[XenaLives]

Key Facts About NervGen
NervGen’s core technology targets a novel receptor called protein tyrosine phosphatase sigma (PTPs).

PTPs is present in the central nervous system (CNS) and the peripheral nervous system (PNS). This receptor plays a key role when there is nerve damage where it impedes nerve regeneration, inhibits plasticity and inhibits remyelination.

Inhibition of the PTPs receptor has been shown to promote regeneration of damaged nerves, increase plasticity and stimulate remyelination in animal models. These effects have been accompanied by improvements of nerve and behavior function in animal models for various medical conditions.

Our lead product is NVG-291, a specific and selective PTPs inhibitor.
We are planning to develop NVG-291 for multiple sclerosis, Alzheimer’s disease, and spinal cord injury.

NVG-291 entered Phase 1 clinical trials in the first half of 2021.
For the latest version of NervGen’s company presentation, please click here.

https://www.nervgen.com/overview/